Literature DB >> 10857829

Unusual immunogammopathy maculopathy.

A C Ho1, W E Benson, J Wong.   

Abstract

PURPOSE: To describe an unusual maculopathy in patients with serum immunogammopathies.
DESIGN: Retrospective observational small case series. PARTICIPANTS: Three patients derived from the clinical retina practices of the authors were noted to have unusual maculopathy.
METHODS: Each patient underwent fluorescein angiography and serum laboratory evaluation. MAIN OUTCOME MEASURE: Findings on fluorescein angiography.
RESULTS: An unusual and atypical macular detachment with or without subretinal precipitates or fundus signs of serum hyperviscosity, such as retinal hemorrhages and dilated retinal veins, may be observed in patients with immunogammopathies such as multiple myeloma, Waldenström's macroglobulinemia, and benign polyclonal gammopathy. Fluorescein angiography shows macular hypofluorescence with no evidence of retinal vascular or retinal pigment epithelial leakage within the macular elevation.
CONCLUSIONS: Patients with atypical unilateral or bilateral macular detachment may be afflicted with a serum immunogammopathy such as multiple myeloma or Waldenström's macroglobulinemia. Diagnostic serum protein electrophoresis and hematology consultation should be considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10857829     DOI: 10.1016/s0161-6420(00)00118-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

1.  Therapy with Chinese medicine in Waldenström's macroglobulinemia-associated retinal detachment.

Authors:  Fan Wang; Bai-Lin Song; Bin Yang
Journal:  Chin J Integr Med       Date:  2011-03-04       Impact factor: 1.978

2.  Multiple myeloma masquerading as diabetic macular oedema.

Authors:  Kavitha Rao; Hemanth Murthy; N S Muralidhar; Padmaja Kumari Rani
Journal:  BMJ Case Rep       Date:  2018-04-17

3.  Bevacizumab therapy and multimodal ultrawide-field imaging in immunogammopathy maculopathy secondary to Waldenström's macroglobulinemia.

Authors:  Lucy T Xu; Robert J Courtney; Justis P Ehlers
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-02       Impact factor: 1.300

4.  Bilateral orbital tumor formation and isolated facial palsy in Waldenstrom's macroglobulinemia.

Authors:  Sushil Kumar; Sima Das; J L Goyal; D Chauhan; V Sangit
Journal:  Int Ophthalmol       Date:  2007-02-16       Impact factor: 2.031

5.  Multimodal imaging in immunogammopathy maculopathy secondary to Waldenstrom's macroglobulinemia: a case report.

Authors:  Hui-Rong Xu; Jie Zhu; Xiao-Yan Xie; Jun Zhu; Fang Chen
Journal:  Int J Ophthalmol       Date:  2022-05-18       Impact factor: 1.645

6.  Bilateral 'vitelliform-like' macular lesions in a patient with multiple myeloma.

Authors:  Javeed M Khan; Vikki McBain; Cynthia Santiago; Noemi Lois
Journal:  BMJ Case Rep       Date:  2010-11-23

7.  SEROUS MACULAR DETACHMENT ASSOCIATED WITH WALDENSTROM MACROGLOBULINEMIA MANAGED WITH IBRUTINIB: A CASE REPORT AND NEW INSIGHTS INTO PATHOGENESIS.

Authors:  Ilya Leskov; Alexander Knezevic; Manjot K Gill
Journal:  Retin Cases Brief Rep       Date:  2021-07-01

8.  Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma.

Authors:  Berna Dogan; Muhammet Kazim Erol; Devrim Toslak; Deniz Turgut Coban; Mehmet Bulut; Ayse Cengiz; Esin Sogutlu Sari
Journal:  Ther Clin Risk Manag       Date:  2015-04-30       Impact factor: 2.423

9.  Hyperviscosity Retinopathy and Immunogammopathy Maculopahy as New Onset of Multiple Myeloma.

Authors:  Natasha Ferreira Santos da Cruz; José Arthur Pinto Milhomens Filho; Desirée Mayara Nery Ferraro; Murilo Ubukata Polizelli; Nilva Simeren Bueno de Moraes Ambrogini
Journal:  Case Rep Ophthalmol       Date:  2021-07-01

Review 10.  Paraneoplastic ocular syndrome: a pandora's box of underlying malignancies.

Authors:  Prathama Sarkar; Amit Mehtani; Harish Chandar Gandhi; Jatinder Singh Bhalla; Satish Tapariya
Journal:  Eye (Lond)       Date:  2021-08-03       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.